These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19575291)

  • 1. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
    Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
    Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
    Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
    Davis AL; Klitus M; Mintzer DM
    Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis.
    Zhao J; Liu J; Chen K; Li S; Wang Y; Yang Y; Deng H; Jia W; Rao N; Liu Q; Su F
    Breast Cancer Res Treat; 2014 May; 145(1):113-28. PubMed ID: 24671358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
    Reh A; Oktem O; Oktay K
    Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
    Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
    Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
    Han HS; Ro J; Lee KS; Nam BH; Seo JA; Lee DH; Lee H; Lee ES; Kang HS; Kim SW
    Breast Cancer Res Treat; 2009 May; 115(2):335-42. PubMed ID: 18506620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.
    Okanami Y; Ito Y; Watanabe C; Iijima K; Iwase T; Tokudome N; Takahashi S; Hatake K
    Breast Cancer; 2011 Jul; 18(3):182-8. PubMed ID: 21394515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian function and childbearing issues in breast cancer survivors.
    Gadducci A; Cosio S; Genazzani AR
    Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
    Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
    ; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
    J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
    Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment for young women with early breast cancer.
    Balduzzi A; Cardillo A; D'Alessandro C; Colleoni M
    Minerva Ginecol; 2007 Oct; 59(5):513-27. PubMed ID: 17912178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.